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treated women with breast cancer in Poland?
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Tamoxifen is the most commonly used drug for treating those patients with breast cancer who are oestrogen receptor 
positive. The main active metabolite of tamoxifen is (Z)-endoxifen whose therapeutic efficacy depends on its plasma 
concentration. A therapeutically effective threshold level has indeed been defined for (Z)-endoxifen above which 
the breast cancer relapse rate is significantly reduced. Such steady-state concentrations are conditional on gene 
polymorphism, principally cytochrome P450 2D6 (CYP2D6), that modulates the activity of the encoded enzymes 
that convert tamoxifen to its active metabolites. This drug’s metabolism however may become significantly altered 
when other medication is concomitantly taken, such as selective serotonin reuptake inhibitors, which inhibit CYP2D6.  
A recent study have demonstrated that the majority of tamoxifen treated women with breast cancer in Poland, may 
not in fact attain the therapeutic threshold levels of (Z)-endoxifen. In such cases, personalising optimal treatment 
should be based on direct monitoring of steady-state plasma concentrations of tamoxifen and its metabolites, which 
can thereby significantly improve therapeutic efficacy.  
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Introduction
Tamoxifen is one of the most widely used drugs in those 
patients with breast cancer expressing oestrogen receptors, 
and is proscribed both in primary and adjuvant therapy. It is 
also recommended for breast cancer prevention in high-risk 
carriers bearing mutations in the BRCA1 and BRCA2 genes 
[1]. This drug belongs to the group of selective oestrogen 
receptor modulators which inhibit tumour progression by 
blocking oestrogen binding to its receptor. When used in 
adjuvant therapy over 5 years, tamoxifen reduces the an-
nual recurrence rate of the disease and mortality rate within 
the first 15 years, by respectively nearly 40% and 30% [2]. 
Prolonging the therapy to 10 years appears to be even more 
beneficial by further reducing the risks of recurrence and 
mortality by respectively another 29% and 25% [3]. However, 
the effectiveness of treatment greatly varies and disease 
recurs in 30–50% of patients that receive tamoxifen as ad-
juvant therapy [2]. Pure tamoxifen, as the pro-drug form, 
has little binding affinity towards the oestrogen receptor 
and hence its therapeutic efficacy is largely dictated by the 
action of enzymes that convert the pro-drug into derivatives 
that demonstrate up to a 100-fold greater anti-oestrogenic 
activity [4, 5]. It becomes metabolised in the liver, primarily 
by the large family of cytochrome P450 (CYP) enzymes; with 
CYP2D6, CYP3A4, CYP3A5 and CYP2C19 being the most 
prominent. Phase II drug metabolising enzymes such as 
sulfotransferases (SULTs) and UDP-glucuronosyltransferases 
(UGTs), continue on the metabolic conversions to more hy-
drophilic forms thereby facilitating excretion from the body. 
The individual enzymes metabolising tamoxifen however, 
exhibit variable activities which are related to the polymor-
phic sequence variants of the genes that encode them.
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Active metabolites of tamoxifen
Hitherto, there have been at least thirty six phase I me-
tabolites of tamoxifen described [6, 7]. Two main metabolic 
pathways lead to the formation of the N-desmethyl-tamox-
ifen metabolite, which is found at the largest concentrations 
in plasma from treated patients, as well as 4-hydroxy-tamox-
ifen. These are then converted to 4-hydroxy-N-desmethyl-ta-
moxifen; termed as endoxifen [8]. Both 4-hydroxy-tamoxifen 
and endoxifen exhibit a 30 to 100 times higher affinity to the 
oestrogen receptor, and suppression of oestrogen-depend-
ent proliferation of the human breast cancer MCF7 cells, 
when compared to N-desmethyl-tamoxifen or the parent 
tamoxifen [4, 5]. In chemical terms, tamoxifen occurs in its 
pure form as the (Z)-isomer, thus its metabolites are mainly 
of this form [9]. Those derivatives of tamoxifen which most 
highly inhibit the oestrogen receptor are the (Z)-isomers of 
endoxifen and 4-hydroxy-tamoxifen with IC50 values (half 
maximal inhibitory concentration) of respectively 3 nmol/L 
and 7 nmol/L [6].
CYP2D6 polymorphism and tamoxifen 
metabolism 
The key enzyme responsible for converting tamoxifen 
into 4-hydroxy-tamoxifen and endoxifen is CYP2D6 [8]. It 
also exhibits the greatest polymorphic variability amongst 
the enzymes metabolising tamoxifen. Currently over 140 
genetic variants (alleles) of CYP2D6, have been so far de-
scribed, many of which are linked to a lack of, or decreased 
activity of the enzyme that it encodes for (based on — 
http://www.cypalleles.ki.se/cyp2d6.htm). CYP2D6 function 
(CYP2D6 phenotype) results from the specific combination 
of the two alleles of the encoding gene (CYP2D6 genotype). 
Depending on their CYP2D6 genotype, every population 
member is classified according to four phenotype groups; 
poor metabolisers (PM), intermediate metabolisers (IM), nor-
mal — extensive metabolisers (EM) or ultra-rapid metabolis-
ers (UM) [10]. The global occurrence of particular CYP2D6 
alleles shows considerable ethnic variability, depending on 
the geographic region and population [11].
Tamoxifen treated women of the IM or PM phenotype 
are shown to have plasma concentrations of (Z)-endoxifen 
up to 75% lower than the normal EM phenotype [12–15]. 
Furthermore, the concentration of this metabolite increases 
with increasing numbers of CYP2D6 alleles encoding the 
functioning enzyme [6, 15]. Likewise the drug’s therapeutic 
efficacy, as measured by the disease-free survival period, 
demonstrates that those patients with impaired tamoxifen 
metabolism may not receive the full benefits of such treat-
ment as compared to patients with the fully functional 
enzyme [16]. Ensuing attempts for CYP2D6 genotyping to 
predict the effectiveness of treatment has however not yet 
provided full and unequivocal outcomes and is still not 
recommended for routine testing [17–19].
Therapeutic concentrations of endoxifen
It is widely recognised that (Z)-endoxifen is the primary 
active metabolite of tamoxifen which is ultimately respon-
sible for the drug’s therapeutic efficacy. Its anti-oestrogenic 
properties are similar to (Z)-4-hydroxy-tamoxifen, nonethe-
less its plasma concentration in tamoxifen treated women is 
several times higher [5, 12, 20]. An endoxifen dose-depend-
ent degradation of the oestrogen receptor has been ob-
served [21], together with global gene expression induced 
by oestrogen in MCF7 breast cancer cells [22], and tumour 
growth inhibition in a MCF7 xenograft bearing mouse model 
[23]. Importantly, such effects were either absent or only 
slightly noticeable at those levels of endoxifen concentra-
tions found in women with the CYP2D6 PM phenotype.
Amongst all the tamoxifen metabolites studied only 
endoxifen, up till now, has demonstrated  a relationship 
between plasma concentrations in treated women with 
a corresponding therapeutic response [13, 24, 25]. Recurrence 
rates were 26% lower in patients with plasma concentrations 
of (Z)-endoxifen greater than 5.97 ng/mL when compared 
to those having lower concentrations, thereby permitting a 
threshold therapeutic concentration to become established 
for the first time [13]. Similarly, a recent study found that 
low (Z)-endoxifen levels (< 14.15 nM; 5.29 ng/mL) were 
associated with a shorter period of time free of disease or 
death as compared to high concentrations of this metabolite 
(> 35 nM; 13.07 ng/mL), where the increased risk, expressed 
as a hazard ratio, was 1.94 [24].
On this basis, it was estimated that over 20% of women 
treated with tamoxifen in the standard daily dose of 20 mg 
may not receive the expected benefits from the applied 
therapy [13, 26]. It has also been shown that increasing the 
daily dose of tamoxifen to 30–40 mg for women with the PM 
and IM phenotypes leads to increased (Z)-endoxifen plasma 
concentrations to greater than or close to the threshold 
value of 5.97 ng/mL [26–29]. It can thus be assumed that it 
is possible to increase treatment efficacy in those selected 
patients with plasma (Z)-endoxifen levels that potentially do 
not reach therapeutic levels, by suitably tailoring the treat-
ment, (i.e. through type of drug and/or dose), to individual 
patient requirements.
Studies conducted at the Maria Sklodowska-Curie Me-
morial Cancer Center and Institute of Oncology in Warsaw on 
280 breast cancer patients showed that plasma concentra-
tions of (Z)-endoxifen, as measured by mass spectrometry, 
in women receiving tamoxifen in the standard 20 mg daily 
dose is on average 5.55 ng/mL [15]; this being one of the 
lowest values of those previously reported from other stud-
ies. Moreover, the unexpectedly large group of women sur-
veyed (60%), achieved (Z)-endoxifen concentrations during 
their treatment which were lower than the reported thera-
peutic threshold value of 5.97 ng/mL. This group included 
over 30% patients possessing both alleles of the CYP2D6 
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gene that encodes the fully functional enzyme. Such find-
ings may indicate that the majority of Polish women treated 
for breast cancer with the standard dose of the drug, have 
insufficiently high concentrations of (Z)-endoxifen and 
therefore will not gain the desired therapeutic effects. Taken 
together with other studies, these results in particular con-
firm that determining the CYP2D6 genotype is of marginal 
significance when making prognoses regarding achievable 
(Z)-endoxifen concentrations.
Monitoring and personalising treatment
It is estimated that genetic variability in the CYP2D6 gene 
can only account for 26–40% of the inter-individual varia-
tion in (Z)-endoxifen concentrations achieved in the plasma 
of women treated with tamoxifen [6, 15, 30]. In contrast, 
the variability in the extent by which the drug’s metabo-
lism is directed towards (Z)-endoxifen formation (Fig. 1), 
expressed by the ratio of (Z)-endoxifen to the summed 
concentrations of tamoxifen and its other metabolites, was 
observed to be CYP2D6 genotype-dependent in more than 
50% [15]. It was also shown that other genetic factors (in-
cluding CYP2C9, CYP2C19 and CYP3A5 polymorphisms), as 
well as non-genetic ones (for instance age and body mass 
index; BMI) may, by around 3%, account for the efficiency 
of converting N-desmethyl-tamoxifen to endoxifen, whilst 
53% is accounted for by the CYP2D6 genotype [24]. Other 
observations indicate that a more rapid excretion of ac-
tive metabolites from the body is associated with genetic 
polymorphism of phase II enzymes, such as SULTs and UGTs, 
which may also modify tamoxifen metabolism and affect 
steady-state concentrations of (Z)-endoxifen [17].
It is currently known that concomitantly taking other 
medication may also significantly affect steady-state con-
centrations of active tamoxifen metabolites. Over 30% of 
patients treated with tamoxifen are besides treated for de-
pression or hot flashes, which are the most common adverse 
effects of such therapy [17]. Some antidepressants, (like 
fluoxetine and paroxetine belonging to the selective sero-
tonin reuptake inhibitors), are potent inhibitors of CYP2D6, 
causing significant decreases in plasma (Z)-endoxifen con-
centrations [14, 17, 20]. This is especially evident in patients 
with the EM phenotype, where metabolite concentrations 
may fall down to levels found even in the PM phenotype. The 
effects of CYP2D6 inhibitors may in part explain such a low 
plasma (Z)-endoxifen concentration in patients treated in 
Poland, where any information on taking other medication 
is usually fragmentary, typically obtained from the patients 
themselves and is not systematically monitored.
Another important factor that significantly impacts on 
the steady-state (Z)-endoxifen concentrations in plasma is 
patient compliance to the treatment regimen. It has been 
shown that up to 50% patients receiving tamoxifen therapy 
for breast cancer, interrupt their treatment before the five 
years has expired [31]. Failure to comply with the therapy is 
more often observed in women with the active CYP2D6 en-
zyme compared to those with the inactive form. The reason 
for this is presumed to be the more frequent appearance of 
distressing side effects of the treatment [32].
The presented facts and observations indicate that per-
sonalising treatment could significantly increase the number 
of patients responding to tamoxifen treatment and thereby 
reduce its side effects. To this end, it seems that direct moni-
toring of plasma tamoxifen and its metabolites is the most 
preferred option for the treated women. Not only does this 
approach enable determining whether (Z)-endoxifen concen-
trations reach the therapeutically effective threshold level, 
but to also assess if low concentrations of this metabolite are 
due to unfavourable metabolic pathways being preferred (i.e. 
characterised by a low ratio of (Z)-endoxifen to the summed 
concentrations of tamoxifen and its other metabolites), or 
Figure 1. CYP2D6 metabolism of tamoxifen directed towards formation of the active metabolite (Z)-endoxifen. Modified [15]. Tam – tamoxifen; 
NDM – N-desmethylo-; gluc – glucuronide
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indeed for other reasons; such as taking medication(s) that 
modify enzyme activity or treatment non-compliance by 
patients (low concentrations of tamoxifen).
Patients with an effective tamoxifen metabolism, bur-
dened with a lower risk of relapse, should be persuaded to 
strictly comply with the therapy, whilst patients with plasma 
(Z)-endoxifen concentrations below the therapeutic thresh-
old and an adverse drug metabolism, should be proposed 
personalised treatment through increasing the daily dose of 
tamoxifen or, if at all possible, by using an alternative drug. 
Work is currently undergoing to also determine whether 
standard doses of tamoxifen can be supplemented with 
pure (Z)-endoxifen [33]. Any final assertion on whether it is 
possible to personalise tamoxifen treatment requires sepa-
rate and adequately controlled multicenter studies. Never-
theless, in the light of the above observations presented, 
a call for undertaking such research appears fully justified.
Conclusions
Until now, studies indicate that a significant proportion 
of breast cancer women undergoing tamoxifen treatment 
do not achieve sufficiently high plasma concentrations of 
(Z)-endoxifen, as shown particularly for Polish women, and 
thus potentially may not share in its therapeutic advan-
tages. The previous proposal of the CYP2D6 genotyping for 
tamoxifen treated women is of very limited value, in both 
predicting how effective the treatment will be, as well as 
knowing whether the therapeutic concentration threshold 
of (Z)-endoxifen can be attained. In the context of person-
alising such treatment and its clinical utility, it appears that 
monitoring steady-state concentrations of tamoxifen and 
its metabolites is the preferred option.
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